There is great progress in the study of the diagnosis of hyperkinetic disorders in China within the latest ten years, but it is not enough. Three features are referred by reanalyzing 281 articles dating from 1997 to 2004 collected by the CJFD: 1) Several editions of diagnostic criteria and diagnostic methods are simultaneously used; 2) Comparing with the rate of utilization of the new edition, the old editions of diagnostic criteria constitute a small percentage ; 3) Diagnostic criteria and diagnostic tools have some shortcomings. Four recommendations maybe help to solve these problems:1) Make parents and teachers advance their acknowledgement of hyperkinetic disorders; 2) Develop and improve the diagnostic criteria and diagnostic tools through more researches; 3) Use advanced scientific apparatuses more widely; 4) Establish a perfect diagnostic system according to our culture.

Objective To investigate the effect of Hydroxychloroquine plus Leflunomide on the lipid profile and disease activity index in patients with rheumatoid arthritis (RA).Methods A total of 140 elderly patients with RA who met the American College of Rheumatology (ACR) criteria were treated with Hydroxychloroquine (Group A,n =70) or leflunomide combined with hydroxychloroquine (Group B,n=70),and 100 healthy volunteers were selected as controls.The lipid profile was compared between the patient groups and control group.Lipid levels,Disease Activity Score 28 (DAS28),erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were measured before treatment and 6 months after treatment between Group A and Group B.Results Compared with the control group,RA patients exhibited higher levels of total cholesterol (TC,P＜0.05),low-density lipoprotein cholesterol (LDL-C,P＜0.05) and triglycerides (TG,P＜0.01),and lower levels of high-density lipoprotein cholesterol (HDL-C,P＜0.05).After 6 months of treatment,the disease activity index (DAS28,P＜0.01),the duration of morning stiffness (P＜0.01),ESR,CRP,swollen joint count (SJC) and tender joint count (TJC) decreased in RA patients,compared with controls (P＜0.01 or 0.05).HDL-C levels increased and LDL-C levels decreased in Groups A and B after treatment,compared with pretreatment (P＜0.05 for all).After treatment,TC levels decreased in Group B,compared with Group A (P＜ 0.05),while TG levels had no significant difference between the two groups (P＞0.05).TC and LDL-C levels,ESR,CRP,DAS28,SJC and TJC were lower in Group B than in Group A (all P＜0.05).Conclusions Hydroxychloroquine in combination with Leflunomide therapy can not only control inflammation but also improve the lipid profile,and is more effective than single-drug therapy.The combination may reduce the risk of atherosclerosis and cardiovascular events in patients with RA.

Objective To explore the clinical efficacy of second-line treatment with Zebutinib for mantle cell lymphoma.Methods Totally 80 patients with mantle cell lymphoma admitted to Ganzhou Cancer Hospital from October 2020 to December 2021 were divided into observation group and control group by lottery method,40 cases in each group.The control group received first-line treatment combined Bendamustine for mantle cell lymphoma,while the observation group received second-line treatment combined with Zebutinib on the basis of first-line treatment.The patients were followed up for 2 years.The clinical efficacy,tumor marker levels,immune function,survival cycle and treatment safety of two groups were evaluated and compared.Results The objective remission rate and disease control rate of observation group were higher than those of control group(P＜0.05).After treatment,the levels of lactate dehydrogenase,β2-microglobulin and carcinoembryonic antigen of observation group were lower than those of control group(P＜0.05).After treatment,the immune function indicators of observation group was better than that of control group(P＜0.05).The progression free survival and overall survival of observation group were higher than those of control group(P＜0.05).Conclusion Zebutinib second-line treatment for mantle cell lymphoma has a good effect,can reduce tumor marker levels,improve patients immune function,prolong patients survival cycle,and has good treatment safety.